AVEN (apoptosis and caspase activation inhibitor) is an anti-apoptotic protein that protects cells from programmed cell death through its interaction with key apoptotic regulators. Mechanistically, AVEN inhibits apoptosis by binding to Apaf-1 and Bcl-xL, preventing caspase activation 1. The protein is widely expressed across tissues including brain, heart, intestine, kidney, lung, and testis 1, and its expression is regulated by estrogens in testicular tissue 2. AVEN expression is dynamically regulated through alternative polyadenylation in response to cardiac injury; 3' UTR lengthening of AVEN after myocardial infarction increases binding sites for miR-30b-5p and miR-30c-5p, reducing AVEN expression and promoting cardiomyocyte apoptosis 3. AVEN downregulation correlates with defective spermatogenesis severity and male factor infertility 2, while differential AVEN expression in granulosa cells associates with embryonic development competence 4. Clinically, AVEN is significantly upregulated in lung adenocarcinoma and serves as an independent prognostic factor for poor overall survival 5. High AVEN expression correlates with advanced tumor stages and promotes cancer cell proliferation, migration, and apoptosis resistance through dysregulation of the lncRNA-AC012236.1/miR-30d-5p-AVEN axis 5. These findings position AVEN as a critical therapeutic target in both cardiac disease and cancer contexts.